At a Glance
Versant Ventures is a venture capital firm based in San Francisco, CA founded in 1999. Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe. The firm focuses on Series A investments across sectors including Biotech. The firm manages $3.3B in assets under management. Notable portfolio companies include Forty Seven, Stemcentrx, FibroGen, Dermira, Portola Pharmaceuticals and NextCure. Creates biotechnology companies from in-house discovery labs using big pharma discipline and scientific rigor.
“Creates biotechnology companies from in-house discovery labs using big pharma discipline and scientific rigor.”
Brad Bolzon
Chairman, Managing Director, Versant Ventures
Carlo Rizzuto
Managing Director, Versant Ventures
Clare Ozawa
Managing Director, Versant Ventures
Robin Praeger
Managing Director/Advisor, Versant Ventures
Tom Woiwode
Managing Director, Versant Ventures
Versant Ventures primarily invests at the Series A stage. This means they focus on companies that are scaling their go-to-market after proving product-market fit.
Versant Ventures is headquartered in San Francisco, CA. Many of their portfolio companies are also based in this region, though they invest across geographies.
Versant Ventures focuses on investments in Biotech. Their portfolio reflects deep expertise and networks within these sectors.
Versant Ventures's typical investment check size ranges from $100K to $5M. Actual amounts may vary based on the stage, sector, and specific opportunity.
Versant Ventures manages approximately $3.3B in assets under management (AUM) across their funds.